Dabur Addresses US FDA Import Alert While Maintaining Business Continuity

Dabur India Ltd ($DABUR) has informed that the US Food and Drug Administration (US FDA) has issued Import Alert 66-40 for certain drug products manufactured at a specific section of its Silvassa facility in Dadra and Nagar Haveli following observations related to data integrity and maintenance practices. The import alert was issued on June 10, 2026, after the regulator reviewed the company’s responses and inspection findings. According to Dabur, the action is limited to a small portion of the plant associated with private-label products that contribute an insignificant share of revenue, while its domestic product portfolio and overall manufacturing operations remain unaffected. The company stated that there are no allegations of product safety violations linked to the order and that the facility continues to operate normally. Dabur is actively working with the US FDA by implementing corrective and preventive action plans to address the identified gaps. The company also noted that multiple internal and independent third-party tests have not identified any out-of-specification issues in its products. To ensure uninterrupted service to customers, Dabur is exploring alternative sourcing arrangements for the US market. The development highlights the importance of regulatory compliance and quality systems in global pharmaceutical and healthcare manufacturing, while the company maintains that the financial and operational impact of the order is not material. Disclaimer: This post is for informational purposes only and not a recommendation to buy or sell any securities. I, or my family, associates, or relatives, may have a financial interest in the securities mentioned.